News

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered an overview of the State of the Science Summit that was held on June 30, 2022, with a variety of expert clinicians from Mount Sinai. [WATCH TIME: 7 minutes]

Effect modification by cognitive status and APOE genotype revealed greater effects of mild behavioral impairment with apathy in those who had normal cognition or in non-APOE ɛ4 groups.

The nephrologist at Mayo Clinic provided insight on new data showing elevated extracellular vesicles of neurovascular origin in women with a history of severe preeclampsia years after pregnancy. [WATCH TIME: 4 minutes]

The FDA expressed concerns about the limitations of the data included in the submission, and recommended that Acadia conduct an additional trial in AD psychosis with pimavanserin (Nuplazid).

In a cohort of patients with NMOSD, more severe depressive symptoms were associated with increased time-varying functional connectivity between the precuneus and temporal cortex.

The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.

Inflammatory coagulation pathway activator positive extracellular vesicles were significantly increased in women with a history of severe preeclampsia compared with controls and those with milder cases.

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]

In addition to significant associations between executive memory and cognition, baseline neurofilament light levels and age trended toward significance.

The chief medical officer and cofounder of Linus Health provided background on the reasoning for the measures used in a new machine learning algorithm that classifies cognitive status. [WATCH TIME: 3 minutes]

During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.

All severities of Alzheimer disease showed statistically significant benefits from the exercise program relative to controls, with more mild groups demonstrating the most improvement.

The assistant director of computational biology at Stanford University discussed the knowns and unknowns of 2 rare missense variants and their associations with decreased Alzheimer disease risk. [WATCH TIME: 4 minutes]

The professor of psychiatry and cell biology at NYU Langone provided insight on new findings that uncover the sources of neuronal damage in Alzheimer disease that may explain the failures of antiamyloid therapies.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.

Using several large-scale cohorts, findings showed that cumulative incidence of Alzheimer disease grows faster with age in R145C variant carriers compared with noncarriers, contradicting prior research results.

The medical director of the Deanna and Sidney Wolk Center for Memory Health provided background on his new study using multimodal digital biomarkers to classify patients with mild cognitive impairment. [WATCH TIME: 5 minutes]

Although 57% and 50% of patients with migraine reported being diagnosed with an anxiety or depressive disorders, respectively, healthcare professional estimated these conditions occurred in just 29% and 30% of patients, respectively.

Across the cohort, 11.6% of patients had impairments in memory, attention, and executive function; however, cognitive status was influenced by severity of anosmia, or loss of taste and smell.

Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]

Non-White participants over 90 years of age who reported a mean of 4 discrimination experiences had significantly worse baseline semantic memory compared with those who reported little/no discrimination.

The associate neurologist-in-chief at Boston Children’s Hospital discussed the 4-copy conundrum and whether treatment decisions differ based on SMN2 copies for patients with spinal muscular atrophy. [WATCH TIME: 2 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A cohort of more than 2000 older Latin American individuals reported a significant difference in cognitive symptoms when they underwent a positive life change during the early phase of the COVID-19 pandemic.

As hospitalizations remain high throughout the COVID-19 pandemic, new data suggests that ICU hospitalization is associated with increased risk of Alzheimer disease and all-type dementia.

The assistant director of computational biology at Stanford University provided background on recent findings of two rare APOE missense variants and reduced risk of Alzheimer disease associated with them. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

The study, expected to begin enrollment in May 2023, will evaluate whether cognitive behavioral therapy delivered by telehealth reduces headache days and disability from migraine compared with CBT plus a preventive medication.

Neurology News Network for the week ending July 30, 2022. [WATCH TIME: 4 minutes]